Search Results - "Kubiak, Michal"

Review of New-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia by Shoukier, Mahran, Kubiak, Michal, Cortes, Jorge

“…Purpose of Review In this review, we analyzed the available data from clinical trials with new tyrosine kinase inhibitors (TKIs) under development and how to…”
Get full text

Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors by Arora, Sanjeevani, Velichinskii, Rodion, Lesh, Randy W., Ali, Usman, Kubiak, Michal, Bansal, Pranshu, Borghaei, Hossein, Edelman, Martin J., Boumber, Yanis

“…In the last few years, immunotherapy has transformed the way we treat solid tumors, including melanoma, lung, head neck, breast, renal, and bladder cancers…”
Get full text

Frequency of and Factors Associated With Nonmedical Opioid Use Behavior Among Patients With Cancer Receiving Opioids for Cancer Pain by Yennurajalingam, Sriram, Arthur, Joseph, Reddy, Suresh, Edwards, Tonya, Lu, Zhanni, Rozman de Moraes, Aline, Wilson, Susamma M, Erdogan, Elif, Joy, Manju P, Ethridge, Shirley Darlene, Kuriakose, Leela, Malik, Jimi S, Najera, John M, Rashid, Saima, Qian, Yu, Kubiak, Michal J, Nguyen, Kristy, PharmD, Wu, Jimin, Hui, David, Bruera, Eduardo

“…One of the main aims of research on nonmedical opioid use (NMOU) is to reduce the frequency of NMOU behaviors through interventions such as universal…”
Get more information

Scheduled and Breakthrough Opioid Use for Cancer Pain in an Inpatient Setting at a Tertiary Cancer Hospital by Rozman de Moraes, Aline, Erdogan, Elif, Azhar, Ahsan, Reddy, Suresh K, Lu, Zhanni, Geller, Joshua A, Graves, David Mill, Kubiak, Michal J, Williams, Janet L, Wu, Jimin, Bruera, Eduardo, Yennurajalingam, Sriram

“…: Our aim was to examine the frequency and prescription pattern of breakthrough (BTO) and scheduled (SCH) opioids and their ratio (BTO/SCH ratio) of use, prior…”
Get full text

Bryozoan carbonate skeletal geochemical composition in the White Sea compared with neighbouring seas by Krzemińska, Małgorzata, Piwoni-Piórewicz, Anna, Shunatova, Natalia, Duczmal-Czernikiewicz, Agata, Muszyński, Andrzej, Kubiak, Michał, Kukliński, Piotr

“…A fundamental question underlying skeletal mineral secretion in marine invertebrates is the extent to which the physico-chemical parameters of seawater (e.g.,…”
Get full text

Meta-Analysis of Pharmacological, Nutraceutical and Phytopharmaceutical Interventions for the Treatment of Cancer Related Fatigue by Yennurajalingam, Sriram, Lu, Zhanni, Rozman De Moraes, Aline, Tull, Nhu Nhu, Kubiak, Michal J, Geng, Yimin, Andersen, Clark R, Bruera, Eduardo

“…Purpose: In this study we aimed to estimate the effectiveness of pharmacological, nutraceutical, and phytopharmaceutical treatments on CRF. Methods: Ovid…”
Get full text

Calcifying Fibrous Tumor Complicated by Empyema by Jain, Nikita, Bharat, Anchit, Marenych, Nadiia, Kubiak, Michal, Khaddour, Karam

“…Calcifying fibrous tumor (CFT) is a rare, benign proliferation of fibroblasts and inflammatory cells that is non-invasive and usually arises in deep tissue…”
Get full text

Age Discrimination (Aspects and Manifestations) in the Perception of Active Seniors by Kubiak, Michał

“…Among many demographic changes, one of the most evident now is the aging of the population, the consequences of which are increasingly leaving a mark on the…”
Get full text

Age Discrimination in the Perce ption of Active Seniors by Kubiak, Michal

“…Among many demographic changes, one of the most evident now is the aging of the population, the consequences of which are increasingly leaving a mark on the…”
Get full text

Challenges of Local Senior Policy and Problems of the Elderly During the COVID-19 Pandemic in the Face of Deinstitutionalisation of Social Services by Kubiak, Michał

“…The COVID-19 pandemic affected the elderly in a special way. On the one hand, it contributed to the increase in health deficits and those related to social…”
Get full text

Membership of European cities and municipalities in the WHO's Global Network of Age-friendly Cities and Communities by Klimowicz, Monika, Kubiak, Michał

“…European society is aging, and it is becoming visible than ever before. The Old World is not only a name identified with the cradle of the Western…”
Get full text

Impact of Qualified Dedicated APL Leukemia Specialist and Simplified Treatment Algorithm on Early Deaths in APL, a Monocenter Experience by Kubiak, Michal Jakub, Jillella, Anand P., Bradshaw, Danielle, Savage, Natasha M., Bryan, Locke J., Kolhe, Ravindra, Kota, Vamsi K.

Get full text

Musculoskeletal Pain Syndrome in a Subset of APL Patients during Induction Therapy by Kubiak, Michal Jakub, Jillella, Anand P., Bradshaw, Danielle, Savage, Natasha M., Kolhe, Ravindra, Bryan, Locke J., Kota, Vamsi K.

Get full text

Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND) by Badar, Talha, Atallah, Ehab, Shallis, Rory, Saliba, Antoine N., Patel, Anand, Bewersdorf, Jan P., Grenet, Justin, Stahl, Maximilian, Duvall, Adam, Burkart, Madelyn, Palmisiano, Neil, Bradshaw, Danielle, Kubiak, Michal, Dinner, Shira, Goldberg, Aaron D., Abaza, Yasmin, Murthy, Guru Subramanian Guru, Kota, Vamsi, Litzow, Mark R.

“…We conducted a multi-center study to analyze factors predicting survival among patients with TP53- mutated (m) AML receiving allogeneic hematopoietic stem cell…”
Get full text

I AM UGLY, BUT NOT CANCER: A CALCIFYING FIBROUS TUMOR IN THE CHEST by Jain, Nikita, Bharat, Anchit, Marenych, Nadiia, Kubiak, Michal, Sheikh, Belaal, Farooqi, Saba, Ward, Wendy, Khaddour, Karam, Shayuk, Maryna

Get full text

Single center experience of using Anakinra prophylactically at Day 0 to reduce CD19 CART toxicities by Nain, Priyanshu, Singh, Rishabh, Yerraguntla, Sandeep, Branham, Zachery, Kubiak, Michal J, Dalgetty, Mark, Pavkov, Isabela, Dontu, Sruthi, Mian, Mohammad, Chauhan, Ayushi, Keruakous, Amany R., Bryan, Locke Johnson, Jillella, Anand P., Kota, Vamsi

“…e19503 Background: Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 is an effective line of the treatment for relapsed/refractory CD19 B cell…”
Get full text

Predictors of Long-Term Outcome in TP53-Mutated Acute Myeloid Leukemia Patients Receiving Allogeneic Stem Cell Transplant after First- or Second-Line Therapy: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND) by Badar, Talha, Atallah, Ehab L., Shallis, Rory Michael, Saliba, Antoine N., Stahl, Maximilian F., Bewersdorf, Jan Philipp, Grenet, Justin, Patel, Anand Ashwin, Abaza, Yasmin, Guru Murthy, Guru Subramanian, Duvall, Adam S, Burkart, Madelyn, Palmisiano, Neil, Kubiak, Michal Jakub, Kota, Vamsi K., Dinner, Shira, Goldberg, Aaron D, Litzow, Mark R.

Get full text

Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL by Roloff, Gregory W, Aldoss, Ibrahim, Kopmar, Noam E, Lin, Chenyu, Dekker, Simone E, Gupta, Vishal K, O'Connor, Timothy E, Jeyakumar, Nikeshan, Muhsen, Ibrahim N, Valtis, Yannis, Ahmed, Naveed, Zhang, Amy, Miller, Katharine, Dykes, Kaitlyn C, Ahmed, Mohamed, Chen, Evan C, Mercadal, Santiago, Schwartz, Marc, Tracy, Sean I, Dholaria, Bhagirathbhai, Mukherjee, Akash, Battiwalla, Minoo, Logan, Aaron C, Ladha, Abdullah, Guzowski, Caitlin, Hoeg, Rasmus T, Hilal, Talal, Moore, Jozal, Connor, Matthew P, Hill, LaQuisa C, Tsai, Stephanie B, Sasine, Joshua P, Solh, Melhem M, Kota, Vamsi K, Koura, Divya, Veeraputhiran, Muthu, Leonard, Jessica T, Frey, Noelle V, Park, Jae H, Luskin, Marlise R, Bachanova, Veronika, Galal, Ahmed, Pullarkat, Vinod, Stock, Wendy, Cassaday, Ryan D, Shah, Bijal D, Faramand, Rawan, Muffly, Lori

“…On the basis of the results of the ZUMA-3 trial, brexucabtagene autoleucel (brexu-cel), a CD19-directed chimeric antigen receptor T-cell therapy, gained US…”
Get full text

Bridging Therapy in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Standard of Care Brexucabtagene Autoleucel: Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA) by Lin, Chenyu, Tsai, Stephanie B., Roloff, Gregory W, Zhang, Amy, Aldoss, Ibrahim, Kopmar, Noam E., Dekker, Simone E., Jeyakumar, Nikeshan, Gupta, Vishal K, O'Connor, Timothy E, Dykes, Kaitlyn C, Ahmed, Mohamed, Dholaria, Bhagirathbhai, Zambrano, Hector, Bradshaw, Danielle, Logan, Aaron C., Tracy, Sean, Kubiak, Michal, Solh, Melhem M., Mercadal, Santiago, Schwartz, Marc, Mukherjee, Akash, Battiwalla, Minoo, Shaughnessy, Paul, Majhail, Navneet, Mountjoy, Luke, Malik, Shahbaz A., Mathews, John, Ladha, Abdullah, Advani, Anjali S., Stefan, Maryann, Guzowski, Caitlin, Hoeg, Rasmus T., Hilal, Talal, Moore, Jozal, O'Dwyer, Kristen M., Sasine, Joshua, Lee, Catherine J., Kota, Vamsi K., Koura, Divya, Veeraputhiran, Muthu, Blunk, Betsy, Leonard, Jessica T., Oliai, Caspian H., Bachanova, Veronika, Stock, Wendy, Pullarkat, Vinod, Cassaday, Ryan D, Miller, Katharine, Muffly, Lori S., Galal, Ahmed, Shah, Bijal D., Faramand, Rawan

“…Introduction: Brexucabtagene autoleucel (brexu-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy approved for adults with…”
Get full text

Impact of Prior Response to Blinatumomab on Outcomes of Brexucabtagene Autoleucel (Brexu-cel) in Adult Patients with Relapsed or Refractory (r/r) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR-T in Adult ALL (ROCCA) by Gupta, Vishal K, Roloff, Gregory W, Muffly, Lori S., Aldoss, Ibrahim, Kopmar, Noam E., Lin, Chenyu, Dekker, Simone E., Jeyakumar, Nikeshan, O'Connor, Timothy E, Zhang, Amy, Miller, Katharine, Dykes, Kaitlyn C, Ahmed, Mohamed, Bradshaw, Danielle, Mercadal, Santiago, Schwartz, Marc, Tracy, Sean, Dholaria, Bhagirathbhai, Kubiak, Michal, Mukherjee, Akash, Majhail, Navneet, Battiwalla, Minoo, Mountjoy, Luke, Malik, Shabaz, Mathews, John, Shaughnessy, Paul, Logan, Aaron C., Ladha, Abdullah, Yaghmour, George, Advani, Anjali S., Stefan, Maryann, Guzowski, Caitlin, Hoeg, Rasmus T., Hilal, Talal, Moore, Jozal, O'Dwyer, Kristen M., Tsai, Stephanie B., Sasine, Joshua, Lee, Catherine J., Kota, Vamsi K., Koura, Divya, Veeraputhiran, Muthu, Blunk, Betsy, Leonard, Jessica T., Stock, Wendy, Galal, Ahmed, Pullarkat, Vinod, Cassaday, Ryan D, Shah, Bijal D., Faramand, Rawan, Oliai, Caspian H.

“…Introduction: Brexucabtagene autoleucel (brexu-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for adults with relapsed…”
Get full text